Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France
- T Lequerré1,
- P Quartier2,
- D Rosellini2,
- F Alaoui3,
- M De Bandt4,
- O Mejjad1,
- I Kone-Paut5,
- M Michel6,
- E Dernis7,
- M Khellaf6,
- N Limal8,
- C Job-Deslandre9,
- B Fautrel10,
- X Le Loët1,
- J Sibilia3,
- on behalf of the Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP) and the Club Rhumatismes et Inflammation (CRI)
- 1Rheumatology Department, Rouen University Hospital & Inserm 905, Rouen, France
- 2Paediatric Immuno-Haematology and Rheumatology Department, Necker-Enfants Malades Hospital, Paris, France
- 3Rheumatology Department, CHU Strasbourg, Strasbourg, France
- 4Rheumatology Department, Hôpital Robert Ballanger, Aulnay sous Bois, France
- 5Paediatric Department, Bicêtre Hospital, Le Kremlin-Bicêtre, France
- 6Department of Internal Medicine, Hôpital Henri Mondor, Créteil, France
- 7Rheumatology Department, Hôpital Le Mans, Le Mans, France
- 8Department of Internal Medicine, Hôpital Pitié Salpétrière, France
- 9Rheumatology A Department, Cochin Hospital, Paris, France
- 10Rheumatology Department, Hôpital Pitié-Salpétrière, Paris, France
- T Lequerré, Rheumatology Department, Rouen University Hospital & Inserm 905, 76031 Rouen, France; . Pierre Quartier, Unité d’Immunologie-Hématologie et Rhumatologie pédiatrique, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France;
- Accepted 23 September 2007
- Published Online First 18 October 2007
Background: Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD).
Objectives: To assess the efficacy and the safety of anakinra treatment in SoJIA and AoSD.
Methods: SoJIA and AoSD patients were treated with anakinra (1–2 mg/kg/day in children, 100 mg/day in adults); we analysed its effect on fever, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, numbers of swollen and tender joints, the assessment of disease activity (by physician and parent/patient) and pain (by parent/patient), and American College of Rheumatology (ACR) pediatric core set criteria for JIA activity.
Results: A total of 35 patients were included, 20 with SoJIA and 15 with AoSD. Their mean age (range) at the onset of treatment was 12.4 (3–23) and 38.1 (22–62) years, respectively; disease duration was 7.0 (1–16) and 7.8 (2–27) years, respectively. Active arthritis was present in all cases but one. Of the 20 SoJIA patients, 5 achieved ACR 50% improvement in symptoms (ACR50) response criteria at 6 months. Steroid dose had been decreased by 15% to 78% in 10 cases. A total of 11 of the 15 AoSD patients achieved at least a 50% improvement for all disease markers (mean follow-up: 17.5 (11–27) months). Steroids had been stopped in two cases and the dose was decreased by 45% to 95% in 12 patients. Two patients stopped anakinra due to severe skin reaction, and two patients due to infection: one visceral leishmaniasis and one varicella.
Conclusion: Anakinra was effective in most AoSD patients, but less than half SoJIA patients achieved a marked and sustained improvement.
See editorial on p 281
TL and PQ contributed equally to this work.
Competing interests: None declared.